Abiopharma

News list

(75% Positive) Crinetics Pharmaceuticals, Inc. (CRNX) Provides Update on program for Crinetics’ business

Full text

News bot Oct. 1, 2025, 10:19 p.m.
📋 Crinetics Pharmaceuticals, Inc. (CRNX) - Clinical Trial Update

Filing Date: 2022-05-25

Accepted: 2022-05-25 07:02:50

Event Type: Clinical Trial Update
Event Details:
Crinetics Pharmaceuticals Inc (CRNX) Announces Clinical Trial Update Crinetics Pharmaceuticals Inc (CRNX) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: program, inherent
Diseases/Conditions: Crinetics’ business, paltusoti
Clinical Stage: clinical trial, Phase 1
Collaboration: FDA
Targeting single efficacious QD dose Cushing’s Disease: Targeting patient specific QD dose range 2 1 Review ‘4894
targeting oncology indications. NETs: Neuroendocrine tumors; GIR: Glucose infusion rate; GC: Glucocorticoid; A4: Androstenedione; HHM: Humoral hypercalcemia of malignancy; NCE: New chemical entity 2021
Targeting the ACTH receptor blocks the key chokepoint of HPA signaling, and could become cornerstone of therapy in CAH and Cushing’s References: Felders et al. Lancet Diab Endo 7:300-12, 2019
💼 Business Developments:
- Partnership
- Acquisition: Not available
- Licensing: Not available
- Regulatory Approval
- Executive Changes: Not available
Structured Data:
- Company Name: Crinetics Pharmaceuticals Inc
- CIK: 0001658247
- Ticker Symbol: CRNX
- Period End Date: 2022-05-25
- Document Type: 8-K